{"audit":{"version":"1.5","generated_at":"2026-11-22T17:53:47.348770+00:00","generated_by":"Agenstry","report_url":"https://agenstry.com/agents/rare-disease-atlas.github.io","methodology_url":"https://agenstry.com/methodology","verifier_jwks_url":"https://agenstry.com/.well-known/jwks.json","subject":{"domain":"rare-disease-atlas.github.io","name":"Rare Disease Venture Atlas Agent","url":"https://rare-disease-atlas.github.io/.well-known/agent-card.json"}},"identity":{"provider":{"organization":"Rare Disease Venture Atlas","url":"https://rare-disease-atlas.github.io"},"registry_verification":null,"signature":{"signed":false,"signature_valid":null}},"protocol":{"version":"0.3.0","supports_streaming":false,"supports_push_notifications":false},"operational":{"live_state":"live","live_responds":true,"last_status_code":200,"last_elapsed_ms":153,"last_error":null},"track_record":{"first_seen":"2026-11-22T14:39:59.774230+00:00","last_checked":"2026-11-22T14:39:59.774230+00:00","last_seen_ok":"2026-11-22T14:39:59.774230+00:00","checks_total":1,"checks_ok":1,"uptime_pct":100.0,"uptime_window_days":30,"uptime_probes":1,"archived":false,"archived_reason":null},"conformance":{"score":59,"grade":"D","summary":"D-grade: significant issues, auth-gated, partially broken, or stale.","criteria":[{"key":"valid_card","label":"Valid AgentCard","points":10,"max_points":10,"status":"pass","detail":"Parseable AgentCard returned by the well-known endpoint (Agenstry readiness signal; not an official TCK certification)."},{"key":"live_responds","label":"Live JSON-RPC","points":25,"max_points":25,"status":"pass","detail":"Endpoint responds to a negotiated A2A SendMessage probe (answers in ~959 ms)."},{"key":"protocol_version","label":"Protocol version","points":5,"max_points":10,"status":"partial","detail":"Declares pre-1.0 A2A 0.3.0 (Google preview). Upgrade to v1.x for full points."},{"key":"signature","label":"JWS signature","points":0,"max_points":10,"status":"info","detail":"Card is unsigned (most published agents are)."},{"key":"uptime","label":"Uptime track record","points":0,"max_points":15,"status":"info","detail":"Only 1 probe so far, need ≥5 for an uptime grade."},{"key":"skills","label":"Skill declaration","points":10,"max_points":10,"status":"pass","detail":"Declares 8 skills with structured metadata."},{"key":"verified_identity","label":"Verified Identity","points":5,"max_points":10,"status":"partial","detail":"Provider declared: Rare Disease Venture Atlas (https://rare-disease-atlas.github.io). Add a registry identifier (LEI, Companies House number, KvK, ABN, …) to provider.legalEntity for full verified-business credit."},{"key":"freshness","label":"Freshness + modern flags","points":4,"max_points":5,"status":"pass","detail":"seen in upstream source within 0d"},{"key":"security","label":"Security declaration","points":0,"max_points":5,"status":"info","detail":"Neither securitySchemes nor securityRequirements declared — how to authenticate is unstated."}]},"card_read":{"findings":[],"clean":true,"source_url":"https://rare-disease-atlas.github.io/.well-known/agent-card.json"},"skills":[{"id":"jak2-clonal-myelofibrosis-diligence","name":"Clonal JAK2 V617F+ Myelofibrosis (JH2 vs JH1) Translational Diligence","description":"Analyzes Type I JH1 JAK inhibitor cytopenia & persistence failure modes, mutant-selective JH2 pseudokinase binders/degraders (INCB160058 NCT06313593, PDB 4FVR/6E2Q/8BAK vs WT 4FVP), Type II persistence breakers (AJ1-11095 NCT06343805), mutant CALR biologics, and single-cell bone marrow datasets (GSE144568, GSE122198).","tags":["myelofibrosis","JAK2-V617F","JH2","JH1","CALR","PROTAC","clinical-trials"],"examples":["Explain JH2 vs JH1 selectivity in JAK2 V617F myelofibrosis and active NCT trials.","Call get_disease_case_study for jak2-myelofibrosis and design a zero-wet-lab JH2 degrader validation plan."],"inputModes":[],"outputModes":[]},{"id":"autoimmune-myelofibrosis-iron-triage","name":"Reversible Autoimmune Myelofibrosis (AIMF) & Dual Iron Overload Positive-Control Triage","description":"Contrasts clonal JAK2+ PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (AIMF: 74-80% hematologic & marrow fibrosis remission on corticosteroids/rituximab) and dual transfusional + IL-6/hepcidin/ferroportin reticuloendothelial iron overload.","tags":["autoimmune-myelofibrosis","AIMF","lupus","SLE","hepcidin","ferroportin","iron-overload","fibrosis-reversal"],"examples":["How does JAK2-negative autoimmune myelofibrosis (AIMF) with lupus suspicion and dual iron overload differ from triple-negative PMF?","Use AIMF as Nature's Positive Control to identify human marrow fibrosis reversal switches."],"inputModes":[],"outputModes":[]},{"id":"stress-test-orphan-hypothesis","name":"Stateless Orphan Hypothesis Red-Team & Biological/Venture Stress-Test","description":"Red-teams candidate drug targets, structural ML binders, diagnostic triage classifiers, or orphan venture theses via POST https://api.rare-disease-atlas.workers.dev/api/stress-test against JH2 vs JH1 selectivity traps, AIMF vs Triple-Negative PMF pathology discordance, Phase 3 endpoint casualties (TRANSFORM-1, IMpactMF), MyelofibrosisBench-v1, and FY2026 FDA Orphan unit economics.","tags":["stress-test","red-team","hypothesis-validation","myelofibrosis","AIMF","JAK2-V617F","MyelofibrosisBench-v1"],"examples":["Stress-test a mutant-selective JAK2 V617F JH2 PROTAC degrader hypothesis via POST https://api.rare-disease-atlas.workers.dev/api/stress-test.","Red-team an EHR + WSI diagnostic triage wedge separating lupus-associated Autoimmune Myelofibrosis from Triple-Negative PMF."],"inputModes":[],"outputModes":[]},{"id":"search-orphan-venture-wedges","name":"Search Orphan Disease Startup Blueprints & 90-Day Validation Plans","description":"Searches concrete rare-disease startup wedges via search_founder_opportunities and generates 30/60/90-day killer-experiment roadmaps via get_90_day_validation_plan across AI/ML drug repurposing, public-health/EHR diagnostics, and venture-philanthropy spinouts.","tags":["rare-disease","venture","biotech","ai-bio","public-health","90-day-plan"],"examples":["Search zero-wet-lab computational AI/ML startup wedges under $250K seed budget and generate a 90-day validation plan.","What public-health diagnostic wedges prevent misdiagnosis of Autoimmune Myelofibrosis?"],"inputModes":[],"outputModes":[]},{"id":"federated-7000-orphan-disease-scan","name":"Live 7,000-Orphan-Disease Federated Diligence Scan","description":"Queries OpenTargets Platform v4, ClinicalTrials.gov v2, and PubMed live via search_any_orphan_indication for any of 7,000+ orphan diseases, pairing FY2026 FDA Orphan Drug ($4,682,003 PDUFA waiver, 7-yr exclusivity) and Rare Pediatric PRV unit economics against Paired Myelofibrosis Flagships.","tags":["orphan-drug","7000-diseases","OpenTargets","ClinicalTrials","PubMed","PRV","diligence"],"examples":["Run search_any_orphan_indication on VEXAS syndrome and Telomere Biology Disorders and benchmark against JAK2 V617F+ and Autoimmune Myelofibrosis.","Evaluate live clinical trial gaps and Rare Pediatric PRV eligibility for Duchenne muscular dystrophy."],"inputModes":[],"outputModes":[]},{"id":"non-dilutive-grant-stacking","name":"Orphan Disease Non-Dilutive Capital & Ethical Community Validation","description":"Lists stackable NIH SBIR/STTR, ARPA-H, MPN Research Foundation, Blood Cancer United TAP, CDCN/Every Cure, and FDA OOPD grants (list_non_dilutive_grants) paired with non-extractive patient-community validation pathways (get_validation_communities).","tags":["grants","SBIR","ARPA-H","non-dilutive","patient-advocacy","ethical-validation"],"examples":["List non-dilutive grants and ethical validation communities for a seed-stage myelofibrosis AI drug repurposing team."],"inputModes":[],"outputModes":[]},{"id":"query-myelofibrosis-molecular-apis","name":"Query Myelofibrosis Molecular, Structural, Comparison & Catalyst Micro-APIs","description":"Queries zero-auth micro-APIs for single-cell & stromal gene signatures (GET /api/gene?symbol=&cohort=&compartment=&q=), JAK2 V617F JH2 vs WT structural pockets (GET /api/pocket?pdb=&domain=&target=&q=), side-by-side Paired Flagship comparisons (GET /api/compare?a=jak2-myelofibrosis&b=autoimmune-myelofibrosis), and upcoming clinical/regulatory catalysts (GET /feeds/catalysts.json & /feeds/myelofibrosis-catalysts.ics).","tags":["molecular-api","gene-signatures","structural-pockets","compare","catalysts","ics-calendar","JAK2-V617F","AIMF"],"examples":["Query GET https://api.rare-disease-atlas.workers.dev/api/gene?symbol=HAMP and /api/pocket?pdb=4FVR.","Compare jak2-myelofibrosis vs autoimmune-myelofibrosis via GET /api/compare and inspect upcoming catalysts in /feeds/catalysts.json."],"inputModes":[],"outputModes":[]},{"id":"submit-research-finding-or-benchmark","name":"Two-Way A2A Research Finding Submission & MyelofibrosisBench-v1 Leaderboard","description":"Accepts citation-backed translational findings, clinical trial readouts, or errata over two-way A2A (prefix message with 'submit finding:' — zero PII, zero auth) and publishes opt-in anonymous MyelofibrosisBench-v1 model evaluations to the live leaderboard (/benchmarks/leaderboard.html & GET /api/leaderboard.json).","tags":["a2a-submission","submit-finding","MyelofibrosisBench-v1","leaderboard","open-science","benchmark"],"examples":["submit finding: NCT06313593 Phase 1 JH2 V617F-selective inhibitor biomarker update for jak2-myelofibrosis.","Fetch live standings from https://api.rare-disease-atlas.workers.dev/api/leaderboard.json and submit an anonymous MyelofibrosisBench-v1 evaluation."],"inputModes":[],"outputModes":[]}],"provenance":[{"source":"lists","first_seen":"2026-11-22T14:39:59.774230+00:00"}],"recent_probes":[{"fetched_at":"2026-11-22T14:39:59.774230+00:00","ok":true,"status_code":200,"error":null,"elapsed_ms":153,"live_responds":true}],"catalog_attestation":null,"operator_revenue_evidence":{"evidence_class":"operator_submitted","authenticity":{"rung":"no_operator_evidence","rank":0,"why":"No verifiable operator evidence has been submitted for this agent.","thresholds":{"min_independent_payers":3,"min_verified_usd":25.0},"engine_table":"agent_authenticity","merge_rule":"max(existing_rank, rank)"},"metric_metadata":{"provenance":"operator_submitted_evidence","confidence":"attested","coverage":{"numerator":0},"as_of":"2026-11-22T17:53:47.358210+00:00","definition":"Revenue proofs submitted by the verified owner and re-checked by Agenstry against the settlement chain or the operator's own Stripe account. Only independently confirmed proofs are counted."},"counts":{"retained":0,"verified":0,"unverifiable":0},"verified":{"gross_usd":0.0,"transactions":0,"independent_payers":0},"detail_url":"https://agenstry.com/api/agents/rare-disease-atlas.github.io/evidence","dispute_url":"https://agenstry.com/agents/rare-disease-atlas.github.io/dispute"},"verification_history":[],"signatures":[{"protected":"eyJhbGciOiJFUzI1NiIsImprdSI6Imh0dHBzOi8vYWdlbnN0cnkuY29tLy53ZWxsLWtub3duL2p3a3MuanNvbiIsImtpZCI6ImFnZW50ZmluZGVyLWVzMjU2LTEiLCJ0eXAiOiJKT1NFIn0","signature":"mEmIWfBDY5LpoS2O18q1XMNHCuDozXBRx50CzFRO0VWoYKWJ5upFToxfR0Mze18mA8F3d5beyEIwSc5n-t46Mg"}]}